[IV: Small group workshop for developing future measures and projects. Evidence-based therapy in rheumatology with special reference to applications of new drugs--formulation of possible goals and possibilities for meeting them. Osteoporosis in rheumatic diseases].
Secondary osteoporosis is a common, late complication of inflammatory rheumatic diseases. Despite its great socio-economic implications for the individual, there is still a lack of appreciation of this problem. This may result in an inadequate or insufficient prophylaxis and therapy. The participants of this discussion group, therefore, approve of further investigations in this field to gather new relevant data, e.g., for our core documentation on rheumatic diseases. Of special importance is the registration of long-term patients obtaining documented, individual long-term therapy (e.g., cortisone). As well as epidemiologic and clinical research projects, it is imperative to do basic research into the pathogenesis of secondary osteoporosis and find new therapeutic approaches for curing rheumatic disease.
Hein
G
G
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D012307:Risk Factors; D013256:Steroids
D000893:Anti-Inflammatory Agents; D013256:Steroids